Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer’s disease: an open-label extension study

INTRODUCTION: Sodium selenate is a potential disease-modifying treatment for Alzheimer’s disease (AD) which reduces hyperphosphorylated tau through activation of the protein phosphatase 2A enzyme. We have shown sodium selenate to be safe and well tolerated in a 24-week, phase 2a double-blind placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vivash, Lucy, Malpas, Charles B, Hovens, Christopher M, Brodtmann, Amy, Collins, Steven, Macfarlane, Stephen, Velakoulis, Dennis, O’Brien, Terence J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679123/
https://www.ncbi.nlm.nih.gov/pubmed/34988458
http://dx.doi.org/10.1136/bmjno-2021-000223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679123/
https://www.ncbi.nlm.nih.gov/pubmed/34988458
http://dx.doi.org/10.1136/bmjno-2021-000223

Ejemplares similares